BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 33915463)

  • 1. A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.
    Muus P; Langemeijer S; van Bijnen S; Blijlevens N; de Witte T
    Leuk Res; 2021 Jun; 105():106573. PubMed ID: 33915463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
    Lancet JE; Duong VH; Winton EF; Stuart RK; Burton M; Zhang S; Cubitt C; Blaskovich MA; Wright JJ; Sebti S; Sullivan DM
    Clin Cancer Res; 2011 Mar; 17(5):1140-6. PubMed ID: 21233404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Jabbour E; Kantarjian H; Ravandi F; Garcia-Manero G; Estrov Z; Verstovsek S; O'Brien S; Faderl S; Thomas DA; Wright JJ; Cortes J
    Cancer; 2011 Mar; 117(6):1236-44. PubMed ID: 20960519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Attar EC; Amrein PC; Fraser JW; Fathi AT; McAfee S; Wadleigh M; Deangelo DJ; Steensma DP; Stone RM; Foster J; Neuberg D; Ballen KK
    Leuk Res; 2013 Sep; 37(9):1016-20. PubMed ID: 23773898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
    Natarajan-Amé S; Park S; Ades L; Vey N; Guerci-Bresler A; Cahn JY; Etienne G; Bordessoule D; Ravoet C; Legros L; Cheze S; Stamatoullas A; Berger E; Schmidt A; Charbonnier A; Chaury MP; Braun T; Fenaux P; Dreyfus F;
    Br J Haematol; 2012 Jul; 158(2):232-237. PubMed ID: 22571447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
    Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
    Howard DS; Liesveld J; Phillips GL; Hayslip J; Weiss H; Jordan CT; Guzman ML
    Leuk Res; 2013 Nov; 37(11):1502-8. PubMed ID: 24075534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
    Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
    Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
    Kurzrock R; Kantarjian HM; Blascovich MA; Bucher C; Verstovsek S; Wright JJ; Pilat SR; Cortes JE; Estey EH; Giles FJ; Beran M; Sebti SM
    Clin Cancer Res; 2008 Jan; 14(2):509-14. PubMed ID: 18223226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
    Awada A; Zhang S; Gil T; de Valeriola D; Lalami Y; De Porre P; Piccart-Gebhart MJ
    Curr Med Res Opin; 2007 May; 23(5):991-1003. PubMed ID: 17519066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
    Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
    Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
    Taylor J; Mi X; Penson AV; Paffenholz SV; Alvarez K; Sigler A; Chung SS; Rampal RK; Park JH; Stein EM; Tallman MS; Sen F; Gönen M; Abdel-Wahab O; Klimek VM
    Lancet Haematol; 2020 Aug; 7(8):e566-e574. PubMed ID: 32735836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.
    Garcia-Manero G; Sekeres MA; Egyed M; Breccia M; Graux C; Cavenagh JD; Salman H; Illes A; Fenaux P; DeAngelo DJ; Stauder R; Yee K; Zhu N; Lee JH; Valcarcel D; MacWhannell A; Borbenyi Z; Gazi L; Acharyya S; Ide S; Marker M; Ottmann OG
    Leukemia; 2017 Dec; 31(12):2799-2806. PubMed ID: 28546581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
    Karp JE; Smith BD; Gojo I; Lancet JE; Greer J; Klein M; Morris L; Levis MJ; Gore SD; Wright JJ; Garrett-Mayer E
    Clin Cancer Res; 2008 May; 14(10):3077-82. PubMed ID: 18483374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
    Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.
    Brandwein JM; Leber BF; Howson-Jan K; Schimmer AD; Schuh AC; Gupta V; Yee KW; Wright J; Moore M; MacAlpine K; Minden MD;
    Leukemia; 2009 Apr; 23(4):631-4. PubMed ID: 19092853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.